surpass cvot tirzepatide results 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

We don't have the brain energy to follow through on things

This real-world data helps your clinician fine-tune your dose trajectory and catch any unusual patterns early

For patients who are not candidates for surgery but still need medical treatment

mitochondria are incapacitated by the primary lesions (oxidative stress, neuroinflammation) in the disorder, leading to ineffective replenishment of cellular energy

The AASLD now recommends identifying MASH candidates using non-invasive tests such as vibration-controlled transient elastography, MR elastography, or enhanced liver fibrosis score rather than liver biopsy, which lowers the barrier to diagnosis and treatment

If you experience, or think you are experiencing, any of the below symptoms, you should seek immediate medical attention